Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 15/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23560445 | 0.93 | CYP2D6 (0.49) | CYP2D6SMN1; SMN2USP2TSHRCYP1A2 | |
| SCHEMBL22856290 | 0.89 | CYP2D6 (0.56) | CYP2D6SMN1; SMN2TSHRCYP2C9CYP3A4 | |
| SCHEMBL18926690 | 0.86 | CYP2D6 (0.56) | CYP2D6SMN1; SMN2USP2TSHRCYP1A2 | |
| SCHEMBL26170521 | 0.85 | CYP2D6 (0.49) | CYP2D6SMN1; SMN2USP2TSHRCYP1A2 | |
| SCHEMBL23560331 | 0.85 | CYP2D6 (0.48) | CYP2D6SMN1; SMN2USP2TSHRCYP1A2 | |
| SCHEMBL21107120 | 0.84 | TSHR (0.41) | TSHR | |
| SCHEMBL23842008 | 0.84 | CYP2D6 (0.35) | CYP2D6SMN1; SMN2USP2TSHRCYP1A2 | |
| SCHEMBL24508755 | 0.82 | CYP2D6 (0.49) | CYP2D6SMN1; SMN2USP2TSHRCYP1A2 | |
| SCHEMBL25110219 | 0.82 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2USP2TSHRCYP1A2 | |
| SCHEMBL22856361 | 0.81 | CYP2D6 (0.51) | CYP2D6SMN1; SMN2USP2TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP2D6 3599/4885SMN1; SMN2 2647/4885USP2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.